Welcome to our dedicated page for Adapthealth SEC filings (Ticker: AHCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles SEC filings for AdaptHealth Corp. (NASDAQ: AHCO), a company that describes itself as a national provider of patient-centered, healthcare-at-home solutions. Its common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on The Nasdaq Stock Market LLC under the ticker AHCO, as disclosed in its current reports.
AdaptHealth’s recent regulatory filings include multiple current reports on Form 8-K. These filings furnish press releases announcing quarterly financial results for periods ended June 30 and September 30, along with updates to financial guidance and information on the closing of dispositions of certain assets in its Wellness at Home segment. The 8-Ks also cover a new capitated partnership with a large integrated delivery network and provide details on the company’s annual meeting of stockholders, including votes on director elections, auditor ratification, and advisory approval of executive compensation.
Through these filings, readers can review how AdaptHealth reports net revenue, net income, and cash flow, and how it discusses non-GAAP measures such as EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, free cash flow, and organic revenue. The company explains in its press releases, furnished as exhibits to the 8-Ks, how these metrics are used in its operational and financial decision-making and how they relate to its credit agreements.
Stock Titan’s SEC filings page presents these AdaptHealth documents with AI-powered summaries that highlight key items, such as earnings announcements, guidance changes, asset sales, and partnership disclosures. Users can quickly locate 8-Ks and related exhibits, and track how the company communicates material events, capital structure developments, and governance matters through the EDGAR system.
AdaptHealth Corp. director Susan T. Weaver reported a bona fide gift of 73,472 shares of AdaptHealth common stock, transferred to the Susan T. Weaver 2025 Irrevocable Trust for the benefit of her spouse and children. The filing lists the transaction as a gift transfer with no sale price.
After these transactions, Weaver directly holds 21,346 shares of AdaptHealth common stock and indirectly holds 73,472 shares through the irrevocable trust, reflecting a shift of ownership to a family estate-planning vehicle rather than a market sale.
AdaptHealth Corp. director Dale B. Wolf reported an open-market purchase of common stock. On February 27, 2026, he bought 8,000 shares of AdaptHealth common stock at a weighted average price of
After this transaction, Wolf directly owned 104,235 common shares. The filing also reports an additional 14,000 common shares held indirectly by a trust, reflecting indirect ownership separate from his direct holdings.
AdaptHealth Corp. insider Richard W. Rew II, the company’s CLO and General Counsel, reported an open-market purchase of 5,000 shares of common stock at $8.91 per share. Following this Form 4 transaction, his directly owned AdaptHealth shareholdings increased to 107,097 shares.
AdaptHealth Corp. filed its annual report describing a large U.S. home-care platform focused on sleep, respiratory, diabetes and broader wellness-at-home products and services. The company operates four segments and, as of December 31, 2025, served about 4.3 million patients through roughly 640 locations in 48 states.
Revenue is diversified across resupply and one-time sales (about 63% of 2025 net revenue), monthly rental equipment (about 33%) and at-risk capitation contracts (about 4%). The report highlights reliance on a few key suppliers, heavy exposure to Medicare, Medicaid and private payors, significant regulatory and reimbursement uncertainty, cybersecurity and AI-related risks, inflation and labor pressures, and potential impacts from new U.S. health and climate-related laws.
AdaptHealth Corp. reported essentially flat 2025 sales but a swing to loss and outlined higher 2026 targets. Net revenue for 2025 was $3,244.9 million, down 0.5%, while net loss attributable to AdaptHealth was $70.8 million versus prior-year net income of $90.4 million, driven in part by a $128.0 million non-cash goodwill impairment in the Diabetes Health unit. Adjusted EBITDA fell 10.5% to $616.7 million, and fourth quarter Adjusted EBITDA declined 18.7% to $163.1 million, including a $14.5 million legal settlement expense and over $10 million of strategic investments. Cash flow from operations remained strong at $601.8 million, up from $541.8 million, with full-year free cash flow of $219.4 million. The company reduced debt by $250 million in 2025 and received credit upgrades from S&P and Moody’s. For 2026, AdaptHealth guides to net revenue of $3.44–$3.51 billion, Adjusted EBITDA of $680–$730 million, and free cash flow of $175–$225 million, reflecting expectations for improved profitability after a transition year.
FMR LLCAbigail P. Johnson report beneficial ownership of 7,631,435.08 shares of AdaptHealth Corp common stock, representing 5.6% of the class as of 12/31/2025. FMR has sole voting power over 7,626,717 shares and sole dispositive power over 7,631,435.08 shares.
The filing states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of AdaptHealth. One or more other persons may receive dividends or sale proceeds, but no such person holds more than five percent of the outstanding common stock.
AdaptHealth Corp.'s Chief Legal Officer and General Counsel, Richard W. Rew II, reported an equity award of 53,688 shares of common stock on January 30, 2026, coded as an acquisition. The filing shows these shares as restricted stock units that will be settled in common stock when they vest.
After this grant, Rew beneficially owned a total of 102,097 shares of AdaptHealth common stock in direct ownership, reflecting his updated equity stake as a senior officer.
AdaptHealth Corp.’s Chief Commercial Officer Russell E. Schuster III reported an equity award of 48,807 shares of common stock on 01/30/2026. The Form 4 shows the transaction coded as an acquisition at a reported price of $0.00 per share, indicating a stock-based grant.
A footnote explains these 48,807 shares are restricted stock units that will be settled in common stock upon vesting. After this award, Schuster beneficially owns 147,813 shares of AdaptHealth common stock in direct form.
AdaptHealth Corp.'s Chief Operating Officer, Toby Scott Barnhart, received a grant of restricted stock units (RSUs). On 01/30/2026, he was awarded 68,330 shares of common stock at a price of $0 per share, classified as an acquisition.
These RSUs will be settled in AdaptHealth common stock upon vesting, meaning the shares are delivered over time as conditions are met. Following this grant, Barnhart beneficially owns 220,654 shares of AdaptHealth common stock in direct ownership.
AdaptHealth Corp.'s Chief Technology Officer, Albert A. Prast, reported an equity award in the form of restricted stock units. On January 30, 2026, he acquired 63,449 shares of common stock at $0 per share, representing restricted stock units that will settle in common stock upon vesting. Following this grant, he beneficially owned 442,907 shares of AdaptHealth common stock in direct ownership.